Abbott Laboratories rated new Buy at Jefferies
Coverage of ABT was started with a Buy rating, Jefferies said. $60 price target. Fears of Humira competition are overdone.
-----
Adobe Systems numbers lowered at ThinkEquity
Shares of ADBE now seen reaching $27, according to ThinkEquity. Estimates also cut, given slower growth in Europe. Hold rating.
-----
Apple added to Best Ideas List at Wedbush
AAPL was placed on the Best Ideas list, Wedbush Securities said. New $530 price target. Company should continue to see solid demand for the iPhone and iPad.
-----
Bed Bath & Beyond estimates, target raised at UBS
Shares of BBBY now seen reaching $62, according to UBS. Estimates also increased on expected solid 2Q11 results. Neutral rating.
-----
CBOE estimates, target boosted at Jefferies
Shares of CBOE now seen reaching $27, according to Jefferies. Estimates also upped, given higher expected volume growth. Hold rating.
-----
Coventry Health downgraded at Wedbush
CVH was downgraded from Neutral to Underperform, Wedbush said. $32 price target. Pricing cycle may be turning for the worse.
-----
FedEx estimates, target cut at Citigroup
Shares of FDX now seen reaching $95, according to Citigroup. Estimates also lowered as data points to slower growth. Buy rating.
-----
FedEx estimates, target lowered at Dahlman Rose
FDX estimates were cut through 2013, Dahlman Rose said. Company is leveraged to slower economic growth. Buy rating and new $120 price target.
-----
Hub Group estimates, target lowered at UBS
Shares of HUBG now seen reaching $32.50, according to UBS. Estimates also lowered on higher macro risk. Neutral rating.
-----
Intercontinental Exchange estimates upped at Jefferies
ICE estimates were boosted through 2012, Jefferies said. Trading activity is improving. Buy rating and $145 price target.
-----
JPMorgan Chase rated new Overweight at Evercore
JPM was initiated with an Overweight rating, Evercore Partners said. $46 price target. Company can continue to gain market share.
-----
Lennar estimates lowered at Citigroup
LEN estimates lowered through 2012, Citigroup said. Macro risks and aggressive use of balance sheet. Maintain Hold rating.
-----
Marvell Technology downgraded at JMP
MRVL was downgraded to Market Perform, JMP Securities said. Estimates also cut, as the company is facing potential growth headwinds.
-----
MGM Resorts upgraded at Morgan Stanley
MGM was upgraded from Equal-weight to Overweight, Morgan Stanley said. $15 price target. Company is leveraged to improving leisure trends in Las Vegas.
-----
Micron Technology estimates lowered at Sterne Agee
MU estimates were cut through 2013, Sterne Agee said. Company is leveraged to lower DRAM pricing. Buy rating and $14 price target.
-----
Molycorp downgraded at JP Morgan
MCP was downgraded to Neutral, JP Morgan said. Estimates also cut, given uncertain pricing and demand. $66 price target.
-----
Moody's downgraded at Benchmark
MCO was downgraded from Buy to Hold, Benchmark said. $29 price target. Company will be hurt by the turbulent market environment.
-----
Mosaic upgraded at CIBC
MOS was upgraded to Sector Outperform, CIBC said. Company is leveraged to higher potash prices. $88 price target.
-----
Nasdaq OMX estimates increased at Jefferies
NDAQ estimates were raised through 2012, Jefferies said. Volumes trends are improving. Hold rating and $27 price target.
-----
Nokia estimates, target reduced at Wedbush
Shares of NOK now seen reaching $6, according to Wedbush. Estimates also cut, as the company is losing market share. Neutral rating.
-----
Progress Energy rated new Outperform at BMO
PGN was initiated with an Outperform rating, BMO Capital said. $18 price target. Company has a significant resource base and deserves a premium valuation.
-----
Prudential target cut at FBR
Shares of PRU now seen reaching $66, according to FBR Capital Markets. Company is being hurt by lower interest rates. Outperform rating.
-----
PSS World Medical numbers reduced at Credit Suisse
Shares of PSSI now seen reaching $27, according to Credit Suisse. Estimates also cut, given lower utilization rates. Outperform rating.
-----
Pulte Homes upgraded at UBS
PHM was upgraded from Neutral to Buy, UBS said. $8 price target. Opportunities arise as new home market bottoms.
-----
Salix Pharmaceutical estimates, target cut at UBS
Shares of SLXP now seen reaching $32, according to UBS. Estimates also lowered to reflect higher equity and fundamental risk. Neutral rating.
-----
Tempur-Pedic rated new Neutral at Goldman
TPX was initiated with a Neutral rating, Goldman Sachs said. Valuation call, based on a $66 price target.
-----
US Steel numbers reduced at Keybanc
Shares of X now seen reaching $45, according to Keybanc. Estimates also cut, given slower growth in Europe. Buy rating.
